Anthrax

Phase I vaccine clinical trial begins

Published in Vaccine Weekly, November 27th, 2002

DynPort Vaccine Company LLC (DVC), which focuses on biodefense vaccines, announced that it will enter into a phase I clinical trial consisting of approximately 70 volunteers for a new, injectable recombinant anthrax vaccine.

The vaccine consists of a highly purified protein, protective antigen. Using recombinant technology and advanced production processes acquired from Avant Immunotherapeutics, Inc. (AVAN), DVC hopes this vaccine will offer a safe, effective product to support the country's need for a new-generation anthrax vaccine.

The phase I trial will be conducted at the Walter Reed Army Institute of Research (WRAIR) in conjunction with the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-11-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry